Evidence map›Paper›PMID 24606882›Full record

ArticleThe American journal of pathology2014

The impact of IFN-γ receptor on SLPI expression in active tuberculosis: association with disease severity.

Nancy L Tateosian, Virginia Pasquinelli, Rodrigo E Hernández Del Pino, Nella Ambrosi, Diego Guerrieri, Sigifredo Pedraza-Sánchez, Natalia Santucci, Luciano D'Attilio, Joaquín Pellegrini, María A Araujo-Solis and 5 more

Open access · hybridAbstract read
In one paragraph

Article in The American journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Nancy L TateosianLaboratory of Immunomodulators, School of Medicine, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-University of Buenos Aires, Buenos Aires, Argentina.
Virginia PasquinelliDepartment of Biological Chemistry, School of Sciences, University of Buenos Aires, Buenos Aires, Argentina.
Rodrigo E Hernández Del PinoDepartment of Biological Chemistry, School of Sciences, University of Buenos Aires, Buenos Aires, Argentina.
Nella AmbrosiLaboratory of Immunomodulators, School of Medicine, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-University of Buenos Aires, Buenos Aires, Argentina.
Diego GuerrieriLaboratory of Immunomodulators, School of Medicine, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-University of Buenos Aires, Buenos Aires, Argentina.
Sigifredo Pedraza-SánchezDepartment of Biochemistry, National Institute of Medical Sciences Salvador Zubirán, Mexico City, Mexico.
Natalia SantucciImmunology Institute, School of Medicine, National University of Rosario, Rosario, Argentina.
Luciano D'AttilioImmunology Institute, School of Medicine, National University of Rosario, Rosario, Argentina.
Joaquín PellegriniDepartment of Biological Chemistry, School of Sciences, University of Buenos Aires, Buenos Aires, Argentina.
María A Araujo-SolisDepartment of Clinic Genetics, Pediatric Hospital, Centro Médico Nacional siglo XXI. Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Rosa M MusellaTisioneumonology Division, Hospital F. J. Muñiz, Buenos Aires, Argentina.
Domingo J PalmeroTisioneumonology Division, Hospital F. J. Muñiz, Buenos Aires, Argentina.
Rogelio Hernandez-PandoDepartment of Pathology, National Institute of Medical Sciences Salvador Zubirán, Mexico City, Mexico.
Verónica E GarciaDepartment of Biological Chemistry, School of Sciences, University of Buenos Aires, Buenos Aires, Argentina.
H Eduardo ChuluyanLaboratory of Immunomodulators, School of Medicine, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-University of Buenos Aires, Buenos Aires, Argentina. Electronic address: echuluyan@fmed.uba.ar.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of Buenos Aires · ARHospital Muñiz · ARInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXNational University of Rosario · ARMexican Social Security Institute · MX

Funding

Signaling pathways that regulate IFN-g production in human tuberculosis.R01AI079007 · NIAID · FACULTAD DE CIENCIAS EXACTAS Y NATURALES DE LA UNIVERSIDAD DE BUENOS AIRES · PI GARCIA, VERONICA EDITH · 2009 to 2012
$287k
NCIRD CDC HHS U38 IP000901NIAID NIH HHS R01 AI079007
6 · The paper itself

Abstract

Interferon (IFN)-γ displays a critical role in tuberculosis (TB), modulating the innate and adaptive immune responses. Previously, we reported that secretory leukocyte protease inhibitor (SLPI) is a pattern recognition receptor with anti-mycobacterial activity against Mycobacterium tuberculosis (Mtb). Herein, we determined whether IFN-γ modulated the levels of SLPI in TB patients. Plasma levels of SLPI and IFN-γ were studied in healthy donors (HDs) and TB patients. Peripheral blood mononuclear cells from HDs and patients with TB or defective IFN-γ receptor 1* were stimulated with Mtb antigen and SLPI, and IFN-γR expression levels were measured. Both SLPI and IFN-γ were significantly enhanced in plasma from those with TB compared with HDs. A direct association between SLPI levels and the severity of TB was detected. In addition, Mtb antigen stimulation decreased the SLPI produced by peripheral blood mononuclear cells from HDs, but not from TB or IFN-γR patients. Neutralization of IFN-γ reversed the inhibition of SLPI induced by Mtb antigen in HDs, but not in TB patients. Furthermore, recombinant IFN-γ was unable to modify the expression of SLPI in TB patients. Finally, IFN-γR expression was lower in TB compared with HD peripheral blood mononuclear cells. These results show that Mtb-induced IFN-γ down-modulated SLPI levels by signaling through the IFN-γR in HDs. This inhibitory mechanism was not observed in TB, probably because of the low expression of IFN-γR detected in these individuals.

Indexed as

Severity of Illness IndexAdultCase-Control StudiesHumansInterferon-gammaSecretory Leukocyte Peptidase InhibitorTuberculosisInterferon-gammaSecretory Leukocyte Peptidase InhibitorSLPI protein, human

Identifiers

PMID24606882
PMCPMC4005967
OpenAlexW51105986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.